Human embryonic stem cell lines created that avoid immune rejection

December 20, 2007

In a groundbreaking experiment published in Cloning & Stem Cells, scientists from International Stem Cell (ISC) Corp. derived four unique embryonic stem cell lines that open the door for the creation of therapeutic cells that will not provoke an immune reaction in large segments of the population. The stem cell lines are “HLA-homozygous,” meaning that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection.

The lines could serve to create a stem cell bank as a renewable source of transplantable cells for use in cell therapy to replace damaged tissues or to treat genetic and degenerative diseases.

“This study has used a novel approach to producing cells that may one day be used to treat large numbers of patients. While there is a great deal of discussion about the possibility of producing stem cells for each patient this approach to therapy is unrealistic because of the enormous costs involved. Rather it is likely that treatment of large numbers of patients by cell therapy will only be possible if methods are found using any one cell line to treat very large numbers of patients. This very exciting paper represents a significant step forward towards the use of such cells in cell therapy,” says Ian Wilmut, PhD, journal Editor-in-Chief and Director of the Centre for Regenerative Medicine at the Queen’s Medical Research Institute, University of Edinburgh.

“Immune reaction is one of the most serious problems facing the development of stem cell therapy, and cell lines of this type may enable us to treat a large number of patients without immune rejection, offering an enormous practical advantage. Further research is required to confirm that the cells produced in this way are able to replace cells that have been lost in human degenerative disease.”

Jeffrey Janus, President of International Stem Cell and colleagues at the company and from the Russian Academy of Medical Sciences, described the successful parthenogenetic activation of human oocytes and the subsequent derivation of cell lines having the morphology and markers characteristic of human embryonic stem cells. In a paper entitled, “HLA Homozygous Stem Cell Lines Derived from Human Parthenogenetic Blastocysts,” the authors emphasize two key factors that would make this technology so valuable for future efforts to generate replacement tissues and organs and to use donor-derived cell repositories to develop cell-based therapies.

First, the four human parthenogenetic stem cell lines, designated as HpSC-Hhom, are HLA (human leukocyte antigen) homozygous. This makes it possible to match the HLA types of a donor and recipient, reducing the chances of provoking an immune reaction against the transplanted donor cells.

Second, the stem cells are derived from unfertilized donor eggs, not from fertilized embryos, so the technique does not carry the same ethical burden.

The future clinical relevance of this work will depend on the ability to reproduce these results and to demonstrate that the stem cell lines can be induced to form pluripotent progenitor cells and, ultimately, to differentiate into specific mature cell types that can be safely and successfully delivered to patients.

The paper was published online ahead of print in the Journal and is available online. The paper is part of the Spring 2008 (Volume 10, Number 1) issue of the Journal, which is published by Mary Ann Liebert, Inc.

External link: www.liebertpub.com/publication.aspx?pub_id=9

Source: Mary Ann Liebert, Inc.

Explore further: Algorithm helps identify elusive genes that express like clockwork

Related Stories

Sequencing of barley genome achieves new milestone

August 25, 2015

Barley, a widely grown cereal grain commonly used to make beer and other alcoholic beverages, possesses a large and highly repetitive genome that is difficult to fully sequence. Now a team led by scientists at the University ...

Scientists develop method for discovering rare cells

August 21, 2015

Scientists of the Hubrecht Institute Utrecht developed a new method for identifying rare cell types by single-cell mRNA sequencing. The newly developed algorithm, called RaceID, is very useful for identifying rare cell types ...

Making bone in the lab

August 20, 2015

Every year there are around 60,000 hip, 50,000 forearm and 40,000 vertebral fractures in the UK. At the Bone and Joint Research Group at the University of Southampton, Professor Richard Oreffo and team have made pioneering ...

X chromosome inactivation

August 19, 2015

Each cell in a woman's body contains two X chromosomes. One of these chromosomes is switched off, because nobody can live with two active X chromosomes. Hendrik Marks and Henk Stunnenberg, molecular biologists at Radboud ...

Recommended for you

New Horizons team selects potential Kuiper Belt flyby target

August 29, 2015

NASA has selected the potential next destination for the New Horizons mission to visit after its historic July 14 flyby of the Pluto system. The destination is a small Kuiper Belt object (KBO) known as 2014 MU69 that orbits ...

Interactive tool lifts veil on the cost of nuclear energy

August 24, 2015

Despite the ever-changing landscape of energy economics, subject to the influence of new technologies and geopolitics, a new tool promises to root discussions about the cost of nuclear energy in hard evidence rather than ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.